Results 191 to 200 of about 53,092 (237)

Collagen-targeted protein nanomicelles for the imaging of non-alcoholic steatohepatitis. [PDF]

Acta Biomater
Wang AL, Mishkit O, Mao H, Arivazhagan L, Dong T, Lee F, Bhattacharya A, Renfrew PD, Schmidt AM, Wadghiri YZ, Fisher EA, Montclare JK.   +11 more
europepmc   +1 more source

Non-Alcoholic Steatohepatitis Patient Characterization and Real-World Management Approaches in Italy. [PDF]

Pragmat Obs Res
Bugianesi E, Miele L, Donnarumma G, Grau K, Mancuso M, Prasad P, Leith A, Higgins V.   +7 more
europepmc   +1 more source

A Novel GLP-1 and FGF21 Fusion Protein for the Treatment of Non-alcoholic Steatohepatitis (NASH). [PDF]

Adv Pharm Bull
Zhang Z, Ma Y, Xie C, He Y, Wang D, Song H, Yuan M, Zhang X.   +7 more
europepmc   +1 more source

[Non-alcoholic steatohepatitis].

Anales de medicina interna (Madrid, Spain : 1984), 1991
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Non-alcoholic steatohepatitis

Medicina Clínica (English Edition), 2022
Non-alcoholic steatohepatitis belongs to the spectrum of metabolic-associated fatty liver diseases characterized by steatosis linked to obesity, diabetes, metabolic syndrome, dyslipidemia and immune-mediated disorders. The main features of MAFLD include high prevalence, heterogeneity, complexity and dynamic disease.
openaire   +4 more sources

Non-alcoholic steatohepatitis

Diagnostic Histopathology, 2023
Steatohepatitis is a common non-infectious inflammatory disease of the liver, ranking 3rd or 4th in the structure of chronic progressive lesions of the organ. The prevalence of non-alcoholic forms of the disease in the population reaches 11–25 %. In obese patients, the pathology occurs 7 times more often than in those with normal weight.
Seung Hyun Lee, Tu Vinh Luong
openaire   +2 more sources

Non-alcoholic steatohepatitis (NASH)

Current Treatment Options in Gastroenterology, 1999
Non-alcoholic steatohepatitis (NASH) is an increasingly common cause of persistently abnormal liver tests. Establishing a diagnosis of NASH requires the secure exclusion of alcohol abuse and hepatitis C as an alternate cause of liver injury. The gold standard of diagnosis is liver biopsy.
, Sorrell, , Mukherjee
openaire   +2 more sources

Metformin in non-alcoholic steatohepatitis

The Lancet, 2001
There is no established treatment for steatohepatitis in patients who are not alcoholics. This disease is a potentially progressive liver disease associated with hepatic insulin resistance. Only a weight-reducing diet in overweight patients has proved effective.
G, Marchesini, M, Brizi, G, Bianchi, S, Tomassetti, M, Zoli, N, Melchionda   +5 more
openaire   +2 more sources

Mechanisms of non-alcoholic steatohepatitis

Alcohol, 2004
In 1980, the term non-alcoholic steatohepatitis was coined to describe a new syndrome occurring in patients who usually were obese (often diabetic) females who had a liver biopsy picture consistent with alcoholic hepatitis, but who denied alcohol use. The causes of this syndrome were unknown, and there was no defined therapy.
Craig J, McClain, Sri Prakash L, Mokshagundam, Shirish S, Barve, Zhenyuan, Song, Daniell B, Hill, Theresa, Chen, Ion, Deaciuc   +6 more
openaire   +2 more sources